Cargando…
Ziv-aflibercept in macular disease
BACKGROUND/AIMS: Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept. Our purpose i...
Autores principales: | Mansour, Ahmad M, Al-Ghadban, Sara I, Yunis, Muhammad H, El-Sabban, Marwan E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518747/ https://www.ncbi.nlm.nih.gov/pubmed/25677668 http://dx.doi.org/10.1136/bjophthalmol-2014-306319 |
Ejemplares similares
-
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016) -
Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019) -
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020) -
One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017) -
Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)